Literature DB >> 28784671

Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.

Mariana Castanheira1, Lalitagauri M Deshpande2, Andrew P Davis2, Paul R Rhomberg2, Michael A Pfaller2,3.   

Abstract

The activity of 7 antifungal agents against 3,557 invasive yeasts and molds collected in 29 countries worldwide in 2014 and 2015 was evaluated. Epidemiological cutoff values (ECVs) published in the Clinical and Laboratory Standards Institute (CLSI) M59 document were applied for species with no clinical breakpoints. Echinocandin susceptibility rates were 95.9% to 100.0% for the 5 most common Candida species, except for the rates for Candida parapsilosis to anidulafungin (88.7% susceptible, 100.0% wild type). Rates of fluconazole resistance ranged from 8.0% for Candida glabrata to 0.4% for Candida albicans Seven Candida species displayed 100.0% wild-type amphotericin B MIC results, and Candida dubliniensis and Candida lusitaniae exhibited wild-type echinocandin MIC results. The highest fluconazole, voriconazole, and posaconazole MIC values for Cryptococcus neoformans var. grubii were 8 μg/ml, 0.12 μg/ml, and 0.25 μg/ml, respectively. Aspergillus fumigatus isolates were 100.0% wild type for caspofungin and amphotericin B, but 3 (0.8%) of these isolates were non-wild type to itraconazole (2 isolates) or voriconazole (1 isolate). Mutations in FKS hot spot (HS) regions were detected among 13/20 Candida isolates displaying echinocandin MICs greater than the ECV (16 of these 20 isolates were C. glabrata). Most isolates carrying mutations in FKS HS regions were resistant to 2 or more echinocandins. Five fluconazole-nonsusceptible C. albicans isolates were submitted to whole-genome sequencing analysis. Gain-of-function, Erg11 heterozygous, and Erg3 homozygous mutations were observed in 1 isolate each. One isolate displayed MDR1 promoter allele alterations associated with azole resistance. Elevated levels of expression of MDR1 or CDR2 were observed in 3 isolates and 1 isolate, respectively. Echinocandin and azole resistance is still uncommon among contemporary fungal isolates; however, mechanisms of resistance to antifungals were observed among Candida spp., showing that resistance can emerge and monitoring is warranted.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  azoles; echinocandins; resistance

Mesh:

Substances:

Year:  2017        PMID: 28784671      PMCID: PMC5610521          DOI: 10.1128/AAC.00906-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Treatment of Scedosporium apiospermum brain abscesses with posaconazole.

Authors:  Ingo K Mellinghoff; Drew J Winston; Geoffrey Mukwaya; Gary J Schiller
Journal:  Clin Infect Dis       Date:  2002-05-16       Impact factor: 9.079

Review 2.  Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature.

Authors:  Florent Morio; Cedric Loge; Bernard Besse; Christophe Hennequin; Patrice Le Pape
Journal:  Diagn Microbiol Infect Dis       Date:  2010-04       Impact factor: 2.803

3.  Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.

Authors:  Claire M Martel; Josie E Parker; Oliver Bader; Michael Weig; Uwe Gross; Andrew G S Warrilow; Nicola Rolley; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

4.  An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicans.

Authors:  Igor Bruzual; Carol A Kumamoto
Journal:  Mol Genet Genomics       Date:  2011-10-05       Impact factor: 3.291

5.  Voriconazole treatment for less-common, emerging, or refractory fungal infections.

Authors:  John R Perfect; Kieren A Marr; Thomas J Walsh; Richard N Greenberg; Bertrand DuPont; Juliàn de la Torre-Cisneros; Gudrun Just-Nübling; Haran T Schlamm; Irja Lutsar; Ana Espinel-Ingroff; Elizabeth Johnson
Journal:  Clin Infect Dis       Date:  2003-04-22       Impact factor: 9.079

6.  Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009).

Authors:  Michael A Pfaller; Gary J Moet; Shawn A Messer; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2010-11-10       Impact factor: 5.948

7.  Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions.

Authors:  Issam I Raad; Ray Y Hachem; Raoul Herbrecht; John R Graybill; Roberta Hare; Gavin Corcoran; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2006-04-11       Impact factor: 9.079

8.  Anidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistance.

Authors:  Ryan K Shields; M Hong Nguyen; Ellen G Press; Cassaundra L Updike; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

9.  Echinocandin Resistance in Candida.

Authors:  David S Perlin
Journal:  Clin Infect Dis       Date:  2015-12-01       Impact factor: 9.079

10.  Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.

Authors:  Michael A Pfaller; Shawn A Messer; Leah N Woosley; Ronald N Jones; Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2013-05-29       Impact factor: 5.948

View more
  39 in total

1.  Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.

Authors:  Ainara Hernando-Ortiz; Estibaliz Mateo; Marcelo Ortega-Riveros; Iker De-la-Pinta; Guillermo Quindós; Elena Eraso
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  The Emerging Threat of Antifungal Resistance in Transplant Infectious Diseases.

Authors:  Ilan S Schwartz; Thomas F Patterson
Journal:  Curr Infect Dis Rep       Date:  2018-02-05       Impact factor: 3.725

3.  Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature.

Authors:  Maria Siopi; Aikaterini Tarpatzi; Eleni Kalogeropoulou; Sofia Damianidou; Alexandra Vasilakopoulou; Sophia Vourli; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.

Authors:  Hsuan-Chen Wang; Ming-I Hsieh; Pui-Ching Choi; Chi-Jung Wu
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

5.  In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Authors:  M A Pfaller; M D Huband; R K Flamm; P A Bien; M Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

6.  Fungemia Surveillance in Denmark Demonstrates Emergence of Non-albicans Candida Species and Higher Antifungal Usage and Resistance Rates than in Other Nations.

Authors:  Mariana Castanheira
Journal:  J Clin Microbiol       Date:  2018-03-26       Impact factor: 5.948

Review 7.  Antifungal Susceptibility Testing: Current Approaches.

Authors:  Elizabeth L Berkow; Shawn R Lockhart; Luis Ostrosky-Zeichner
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

8.  Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Maria-Ioanna Beredaki; Panagiota-Christina Georgiou; Maria Siopi; Lamprini Kanioura; David Andes; Maiken Cavling Arendrup; Johan W Mouton; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

9.  APX001A In Vitro Activity against Contemporary Blood Isolates and Candida auris Determined by the EUCAST Reference Method.

Authors:  Maiken Cavling Arendrup; Anuradha Chowdhary; Karen M T Astvad; Karin Meinike Jørgensen
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

10.  Antifungal Susceptibility of Clinical Yeast Isolates from a Large Canadian Reference Laboratory and Application of Whole-Genome Sequence Analysis To Elucidate Mechanisms of Acquired Resistance.

Authors:  Lisa R McTaggart; Ana Cabrera; Kirby Cronin; Julianne V Kus
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.